Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 4/20 | 0.42 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | RARG | P13631 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8458838 | 0.88 | RXRA (0.56) | ACE2RXRAKDM4EFABP3FABP4 | |
| SCHEMBL8081677 | 0.83 | KDM4E (0.55) | RXRAKDM4ERXRBRXRGRARA | |
| SCHEMBL9622332 | 0.82 | FABP3 (0.41) | ACE2RXRAFABP3FABP4RXRB | |
| SCHEMBL9622174 | 0.82 | PTPN1 (0.56) | ACE2RXRAFABP3FABP4RXRB | |
| SCHEMBL28355059 | 0.80 | BCL2 (0.58) | RXRAKDM4EFABP3FABP4SMN1; SMN2 | |
| SCHEMBL29386062 | 0.79 | FABP3 (0.48) | ACE2FABP3FABP4EIF4A3 | |
| SCHEMBL9622171 | 0.79 | RARA (0.51) | ACE2RXRAKDM4EFABP3FABP4 | |
| SCHEMBL8461652 | 0.79 | GRIN2D (0.50) | ACE2RXRAKDM4EFABP3FABP4 | |
| SCHEMBL11576784 | 0.78 | NPC1 (0.55) | SMN1; SMN2 | |
| SCHEMBL3307626 | 0.78 | FABP3 (0.57) | ACE2RXRAKDM4EFABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208001-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2005-09-22 | — | — | US | disclosed |
| US-20030013734-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | MAIGNAN JEAN (FR) | 2003-01-16 | — | — | US | disclosed |
| EP-1227791-A2 | USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARS-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION | L'OREAL (FR) | 2002-08-07 | — | — | EP | disclosed |
| US-20020049250-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2002-04-25 | — | — | US | disclosed |
| WO-2001045663-A2 | USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION | L'OREAL (FR) | 2001-06-28 | — | — | WO | disclosed |
| WO-1999048529-A1 | RETINOID-GLITAZONE COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-30 | — | — | WO | disclosed |
| EP-0808159-A1 | USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-5093516-A | AROMATIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND FOR COSMETIC COMPOSITIONS | L'OREAL (FR) | 1992-03-03 | — | — | US | disclosed |
| US-5023363-A | Antiinflammatory agent, antiallergens, skin disorders, vision defects | L'OREAL (FR) | 1991-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049250-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | ACE2 2389/4885RXRA 6/4885KDM4E 4075/4885 |
| US-20030013734-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | ACE2 2389/4885RXRA 6/4885KDM4E 4075/4885 |
| US-20050208001-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | ACE2 2386/4885RXRA 6/4885KDM4E 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.